N-(2-ethoxyphenyl)-N-methyl-2-oxo-1H-quinoline-6-sulfonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(2-ethoxyphenyl)-N-methyl-2-oxo-1H-quinoline-6-sulfonamide
• 化学式: C₁₈H₁₈N₂O₄S
• 分子量: 358.4
• InChiKey: WAFATMGHCBOETO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  84.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF
  申请人：Kahne Suzanne Walker

  公开号：US20120108605A1

  公开（公告）日：2012-05-03

  The present invention provides inhibitors of O-GIcNAc transferase. Typically, the inhibitors are quinolinone-6-sulfonamides. The invention also provides pharmaceutical compositions thereof and methods for using the same in diabetes and complications thereof, neurodegenerative diseases, cancers, autoimmune diseases, and inflammatory diseases.

  本发明提供了O-GIcNAc转移酶的抑制剂。通常，这些抑制剂是喹啉酮-6-磺酰胺。本发明还提供了其制药组合物以及在糖尿病及其并发症、神经退行性疾病、癌症、自身免疫疾病和炎症性疾病中使用它们的方法。
• Methods and Compositions for Modulating Glycosylation
  申请人：Walker Kahne Suzanne

  公开号：US20090325944A1

  公开（公告）日：2009-12-31

  The invention relates to methods and products for modulating glycosylation of proteins. The invention is useful for treating glycosylation-associated disorders such as neurodegeneration, diabetes, including complications of diabetes such as insulin resistance, nephropathy, microvascular damage, and endothelial dysfunction. The invention also relates in part to assays that are useful for identifying and testing candidate compounds for modulating glycosylation of proteins.
• METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE
  申请人：Design Therapeutics, Inc.

  公开号：US20210238226A1

  公开（公告）日：2021-08-05

  The present disclosure relates to compounds and methods for modulating the expression of dmpk, atxn1, atxn2, atxn3, cacna1a, atxn7, ppp2r2br tbp, htt, jph3r ar, or atn1 and treating diseases and conditions in which dmpk, atxn1, atxn2, atxn3, cacna1a, atxn1, ppp2r2b, tbp, htt, jph3, ar, or atn1 plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.
• US8957075B2
  申请人：——

  公开号：US8957075B2

  公开（公告）日：2015-02-17
• [EN] METHODS AND COMPOSITIONS FOR MODULATING GLYCOSYLATION<br/>[FR] PROCEDES ET COMPOSITIONS PERMETTANT DE MODULER LA GLYCOSYLATION
  申请人：HARVARD COLLEGE

  公开号：WO2007120638A2

  公开（公告）日：2007-10-25

  [EN] The invention relates to methods and products for modulating glycosylation of proteins. The invention is useful for treating glycosylation-associated disorders such as neurodegeneration, diabetes, including complications of diabetes such as insulin resistance, nephropathy, microvascular damage, and endothelial dysfunction. The invention also relates in part to assays that are useful for identifying and testing candidate compounds for modulating glycosylation of proteins.
  [FR] L'invention porte sur des procédés et des produits permettant de moduler la glycosylation des protéines. L'invention est utile pour traiter des troubles associés à la glycosylation tels que la neurodégénérescence, le diabète et ses complications dont la résistance à l'insuline, la néphropathie, les dommages microvasculaires et le dysfonctionnement endothélial. L'invention porte également en partie sur des dosages qui sont utiles pour identifier et tester des composés candidats pour moduler la glycosylation de protéines.